159 related articles for article (PubMed ID: 21427555)
1. Molecular predictors of response to chemotherapy in colorectal cancer.
Dienstmann R; Vilar E; Tabernero J
Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
[TBL] [Abstract][Full Text] [Related]
2. Development of molecular biomarkers in individualized treatment of colorectal cancer.
De Mattos-Arruda L; Dienstmann R; Tabernero J
Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
[TBL] [Abstract][Full Text] [Related]
3. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
Le Tourneau C; Vidal L; Siu LL
Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
5. Molecular markers in the treatment of metastatic colorectal cancer.
Wilson PM; Labonte MJ; Lenz HJ
Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
[TBL] [Abstract][Full Text] [Related]
6. Predictive molecular classifiers in colorectal cancer.
Bohanes P; LaBonte MJ; Winder T; Lenz HJ
Semin Oncol; 2011 Aug; 38(4):576-87. PubMed ID: 21810517
[TBL] [Abstract][Full Text] [Related]
7. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.
Yarom N; Jonker DJ
Discov Med; 2011 Feb; 11(57):95-105. PubMed ID: 21356164
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
Asghar U; Hawkes E; Cunningham D
Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
[TBL] [Abstract][Full Text] [Related]
9. Integration of anti-vascular endothelial growth factor therapies with cytotoxic chemotherapy in the treatment of colorectal cancer.
Oliveira SC; Machado KK; Sabbaga J; Hoff PM
Cancer J; 2010; 16(3):220-5. PubMed ID: 20526100
[TBL] [Abstract][Full Text] [Related]
10. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
Dempke WC; Heinemann V
Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
Okada Y; Miyamoto H; Goji T; Takayama T
Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
[TBL] [Abstract][Full Text] [Related]
12. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
13. Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy.
Serrano C; Markman B; Tabernero J
Cancer J; 2010; 16(3):226-34. PubMed ID: 20526101
[TBL] [Abstract][Full Text] [Related]
14. Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies.
Italiano A
Oncology; 2006; 70(3):161-7. PubMed ID: 16675911
[TBL] [Abstract][Full Text] [Related]
15. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
Sangha R; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
[TBL] [Abstract][Full Text] [Related]
16. Molecular predictors of response to antiangiogenesis therapies.
Gerger A; LaBonte M; Lenz HJ
Cancer J; 2011; 17(2):134-41. PubMed ID: 21427557
[TBL] [Abstract][Full Text] [Related]
17. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.
Giampieri R; Scartozzi M; Del Prete M; Maccaroni E; Bittoni A; Faloppi L; Bianconi M; Cecchini L; Cascinu S
Crit Rev Oncol Hematol; 2013 Nov; 88(2):272-83. PubMed ID: 23806981
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer.
Hansen TF; Jakobsen A
Pharmacogenomics; 2011 Dec; 12(12):1681-93. PubMed ID: 22118052
[TBL] [Abstract][Full Text] [Related]
19. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Zhang J; Roberts TM; Shivdasani RA
Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
[TBL] [Abstract][Full Text] [Related]
20. Targeted treatments in colorectal cancer: state of the art and future perspectives.
Arnold D; Seufferlein T
Gut; 2010 Jun; 59(6):838-58. PubMed ID: 20551469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
